Health / WORLD

UK MHRA extends Casgevy gene-editing approval to children aged five and over

The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

Casgevy (exagamglogene autotemcel) was previously restricted to patients aged 12 and above. The therapy edits the patient’s harvested haematopoietic stem cells in a laboratory to reactivate fetal haemoglobin production, before reinfusing them following myeloablative conditioning.

The regulator confirmed that the expansion follows evaluation of clinical trials demonstrating significant reductions in vaso-occlusive pain crises and transfusion dependency in younger age cohorts. Treatment requires specialized cell-therapy centres and rigorous post-infusion monitoring for complications such as cytopenias and infections.

Data

Timeline

Source publication

Publication of the official approval extension announcement on 29 October 2026.

  1. · Occurred

    MHRA expands Casgevy age authorisation to children aged 5 and over

    Regulatory extension granted on 29 October 2026 for pediatric sickle-cell and beta-thalassaemia patients.

Methodology

The date records publication of the cited primary source. Regulatory scope and age indications are stated in the article.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • United Kingdom · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
    • Explicit preserved editorial country/region; no city or national centroid inferredwww.gov.uk ↗
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

UK MHRA grants conditional approval for triheptanoin in rare metabolic disorders

The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.

Medicines and Healthcare products Regulatory Agency, United Kingdom1 min read Data included
Health

UK confirms indefinite recognition of CE-marked medical devices in Great Britain

The UK government and MHRA announced on 21 October that medical devices certified under the EU Medical Devices Regulation and In Vitro Diagnostic Regulation will be recognized indefinitely in Great Britain, while legacy directive transition timelines are extended to 2028.

Medicines and Healthcare products Regulatory Agency, United Kingdom1 min read Data included
Health

United Therapeutics completes first UThymoKidney xenotransplant in EXTEND trial

United Therapeutics announced on 20 November 2026 that surgeons at NYU Langone Health performed the first porcine thymokidney transplant in its EXTEND Phase 1/2/3 trial for end-stage renal disease. The investigational organ uses a single gene edit and porcine thymic tissue and remains unapproved.

United Therapeutics Corporation, First Transplant in EXTEND Clinical Trial of UThymoKidney5 min read Data included